AU2021360767A1 - Methods of treating fibrosis - Google Patents

Methods of treating fibrosis Download PDF

Info

Publication number
AU2021360767A1
AU2021360767A1 AU2021360767A AU2021360767A AU2021360767A1 AU 2021360767 A1 AU2021360767 A1 AU 2021360767A1 AU 2021360767 A AU2021360767 A AU 2021360767A AU 2021360767 A AU2021360767 A AU 2021360767A AU 2021360767 A1 AU2021360767 A1 AU 2021360767A1
Authority
AU
Australia
Prior art keywords
fibrosis
hydrogen
taladegib
treatment
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021360767A
Other languages
English (en)
Other versions
AU2021360767A9 (en
Inventor
Miguel De Los Rios
Anita J. DIFRANCESCO
John Hood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endeavor Biomedicines Inc
Original Assignee
Endeavor Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endeavor Biomedicines Inc filed Critical Endeavor Biomedicines Inc
Publication of AU2021360767A1 publication Critical patent/AU2021360767A1/en
Publication of AU2021360767A9 publication Critical patent/AU2021360767A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021360767A 2020-10-13 2021-10-13 Methods of treating fibrosis Pending AU2021360767A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091128P 2020-10-13 2020-10-13
US63/091,128 2020-10-13
PCT/US2021/054713 WO2022081661A1 (en) 2020-10-13 2021-10-13 Methods of treating fibrosis

Publications (2)

Publication Number Publication Date
AU2021360767A1 true AU2021360767A1 (en) 2023-04-27
AU2021360767A9 AU2021360767A9 (en) 2024-02-08

Family

ID=81209448

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021360767A Pending AU2021360767A1 (en) 2020-10-13 2021-10-13 Methods of treating fibrosis

Country Status (8)

Country Link
US (4) US11628167B2 (enExample)
EP (1) EP4229828A4 (enExample)
JP (1) JP2023546536A (enExample)
KR (1) KR20230107568A (enExample)
CN (1) CN116349204A (enExample)
AU (1) AU2021360767A1 (enExample)
CA (1) CA3198661A1 (enExample)
WO (1) WO2022081661A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
CN116349204A (zh) 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
AU2024230449A1 (en) * 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (enExample) 1977-06-03 1981-03-07 Pfizer
ZA97288B (en) 1996-01-15 1998-07-14 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
CA2326654C (en) 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
ES2233383T3 (es) 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
AU2003231032B2 (en) 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
KR20200019263A (ko) 2004-09-02 2020-02-21 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
EP2137162B1 (en) 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
ES2505091T3 (es) 2007-06-25 2014-10-09 Amgen Inc. Compuestos, composiciones y métodos de uso de ftalazina
US8222251B2 (en) 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
US7981892B2 (en) 2008-04-29 2011-07-19 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2732101C (en) 2008-08-04 2013-09-17 Amgen Inc. Aurora kinase modulators and methods of use
PE20110433A1 (es) 2008-11-03 2011-07-09 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
US20110183948A1 (en) 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
WO2015120257A2 (en) * 2014-02-06 2015-08-13 The Brigham And Women's Hospital, Inc. Uses of gli1 in detecting tissue fibrosis
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
JP2018535238A (ja) 2015-11-30 2018-11-29 イグナイタ インコーポレイテッド 局所製剤
CN109890390A (zh) * 2016-11-04 2019-06-14 上海瑛派药业有限公司 Hedgehog通路抑制剂在治疗纤维化疾病中的应用
US11154541B2 (en) 2018-06-29 2021-10-26 The Trustees Of Indiana University Methods for treating aortic valve stenosis with a hedgehog pathway inhibitor
CN112449602A (zh) * 2018-07-19 2021-03-05 瓦里安医疗系统公司 超高剂量率辐射和治疗剂的使用方法
CN116349204A (zh) * 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
AU2024230449A1 (en) 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis

Also Published As

Publication number Publication date
US11628167B2 (en) 2023-04-18
CA3198661A1 (en) 2022-04-21
US20240342170A1 (en) 2024-10-17
AU2021360767A9 (en) 2024-02-08
KR20230107568A (ko) 2023-07-17
JP2023546536A (ja) 2023-11-02
US20230201195A1 (en) 2023-06-29
WO2022081661A1 (en) 2022-04-21
EP4229828A4 (en) 2024-08-28
US12295954B2 (en) 2025-05-13
US20220265650A1 (en) 2022-08-25
CN116349204A (zh) 2023-06-27
EP4229828A1 (en) 2023-08-23
US20250235452A1 (en) 2025-07-24
US12213974B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
US12213974B2 (en) Methods of treating fibrosis
US12605377B2 (en) Methods of treating fibrosis
AU2024230449A1 (en) Methods of treating fibrosis
JP6170040B2 (ja) ピルフェニドン及び選択された患者における抗線維化療法
JP2022514121A (ja) がんの処置における使用のためのｂｔ１７１８
Donohue et al. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD
US20150005355A1 (en) Combination therapy with parp inhibitors
JP2024178168A (ja) ブルトン型チロシンキナーゼ阻害薬を用いて慢性自発性蕁麻疹を治療する方法
CN108883311A (zh) 布罗莫结构域和额外末端蛋白抑制剂组合疗法
CN113811301A (zh) 使用布鲁顿酪氨酸激酶抑制剂治疗舍格伦综合征的方法
TWI750129B (zh) 作為血液學毒性生物標記之ｇｄｆ-１５
US20200368246A1 (en) Combination therapy targeting cancer associated with the hedgehog pathway
AU2022231038A1 (en) Treatment of copper disorders
Ebbehøj et al. Recovery after laparoscopic parastomal hernia repair
McCulloch et al. R-BAC maintains high response rate in mantle cell lymphoma following relapse on BTK inhibitor therapy
Ohta et al. Effects of benidipine, a long-acting T-type calcium channel blocker, on home blood pressure and renal function in patients with essential hypertension: a retrospective,‘real-world’comparison with amlodipine
WO2020234780A1 (en) Methods of treating asthma using a bruton's tyrosine kinase inhibitor
US20080280867A1 (en) Combination therapy with parp inhibitors
US20230172872A1 (en) Use of an rxr agonist and taxanes in treating her2+ cancers
WO2023108140A1 (en) Method of treating cancer having an activated hedgehog pathway
AU2022407454A1 (en) Use of an rxr agonist in treating drug resistant her2+ cancers
JP2005531622A5 (enExample)
Zeitlinger Drug interactions medicine

Legal Events

Date Code Title Description
SREP Specification republished